表紙
市場調査レポート

ラミブジンの中国市場の分析

Investigation Report on China Lamivudine Market, 2010-2019

発行 China Research and Intelligence 商品コード 334093
出版日 ページ情報 英文 35 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
ラミブジンの中国市場の分析 Investigation Report on China Lamivudine Market, 2010-2019
出版日: 2015年07月02日 ページ情報: 英文 35 Pages
概要

ラミブジンはB型肝炎ウイルスやHIV/AIDSの有力な治療薬の一つで、中国政府からAIDS患者に無償で提供されています (B型肝炎を併発していない場合)。北米諸国では1990年代年半にまずAIDS治療薬として認証され、1998年にはB型肝炎治療薬としても認証されました。中国でも1999年にB型肝炎治療薬として認証されています。それ以来、中国のラミブジン市場は、2012年までは急速な成長を続けてきましたが、2013年になって成長率の低下が見られます。

当レポートでは、中国におけるラミブジンの市場について分析し、全体的な市場規模の動向(過去5年間分)や国内価格の動向、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査・推計しております。

第1章 ラミブジンの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のラミブジン市場の概況

  • 中国国内でのラミブジンの特許出願・認証状況
  • 主要メーカー
  • 市場規模

第3章 ラミブジンの販売状況の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 中国のラミブジン市場:主要メーカーの市場シェアの分析 (過去5年間分)

  • 市場シェア (販売額ベース)
  • 市場シェア (販売量ベース)

第5章 中国のラミブジン市場:剤形別の分析 (過去5年間分)

  • 剤形別の市場シェア (販売額ベース)
  • 剤形別の市場シェア (販売量ベース)

第6章 ラミブジンの病院向け基準価格

  • Beijing Wansheng Pharmaceutical Co., Ltd (商標名:Wanshenglike)
  • Burroughs Wellcome & Company (英国) (商標名:Heptodin)
  • Anhui Biochem United Pharmaceutical Co., Ltd (商標名:Yinding)
  • Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd (商標名:Jianganling)
  • Fujian Cosunter Pharmaceutical Co., Ltd (商標名:Heganding)
  • GlaxoSmithKline Pharmaceuticals (Suzhou) Limited (商標名:Heptodin)

第7章 中国国内のラミブジンの主要メーカー (過去5年間分)

  • Anhui Biochem United Pharmaceutical Co., Ltd
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • GlaxoSmithKline Pharmaceuticals (Suzhou) Limited
  • Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd

第8章 中国のラミブジン市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の見通し

図表一覧

目次
Product Code: 1507254

Acoording to the report issued by the Joint United Nations Programme on HIV and AIDS in 2014, by the end of 2013, patients with human immune deficiency virus/acquired immune deficiency syndrome (HIV/ AIDS) had amounted to 35 million and the number of new cases of HIV/AIDS had been 6000 a day on average. And by the end of 2011, patients with HIV/ AIDS in China was estimated to be 0.78 million, the number of new cases of HIV/AIDS was 48,000 and people die of diseases related with AIDS reached 28,000.

Lamivudine, an important drug for hepatitis B Virus (HBV) and AIDS, is one of the products regulated by the Chinese government to be provided to patients with AIDS (patients with hepatitis B not included) for free. As an antiviral nucleotide analog, lamivudine can competitively inhibit the synthesis and elongation of viral DNA chain. First used by some countries in Europe and North America for the treatment of AIDS in the early 1990s, lamivudine was approved by FDA to be used for the treatment of hepatitis B in 1998 after some medical experts discovered its inhibiting effect on HBV DNA in the middle 1990s. Lamivudine was approved by CFDA mainly as hepatitis B drug and began its sales in China in 1999.

Lamivudine develops fast after entering China with sales value reaching up to CNY 307 million in 2012 despite its gradual drop since 2013. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited, Beijing Wansheng Pharmaceutical Co., Ltd, Burroughs Wellcome & Company (UK) and Fujian Cosunter Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline Pharmaceuticals (Suzhou) Limited had the largest market share of about 72% for sales value in 2014.

With the large amounts of patients with hepatitis B and AIDS in China, the market size of lamivudine is expected to have growth potential.

Readers can get at least the following information from this report:

  • market size of lamivudine in China
  • competitive landscape of lamivudine in Chinese market
  • price of lamivudine made by different enterprises in China
  • market outlook of lamivudine in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-HBV drugs
  • manufacturers of anti-AIDS drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Lamivudine

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Lamivudine in China

  • 2.1. Patent and Approval Status of Lamivudine in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Lamivudine in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Lamivudine in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Lamivudine in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Lamivudine in Chinese Hospitals in 2014

  • 6.1. Beijing Wansheng Pharmaceutical Co., Ltd (Trade Name: Wanshenglike)
  • 6.2. Burroughs Wellcome & Company (UK) (Trade Name: Heptodin)
  • 6.3. Anhui Biochem United Pharmaceutical Co., Ltd (Trade Name: Yinding)
  • 6.4. Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd (Trade Name: Jianganling)
  • 6.5. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: Heganding)
  • 6.6. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited (Trade Name: Heptodin)

7. Major Manufacturers of Lamivudine in Chinese Market, 2010-2014

  • 7.1. Anhui Biochem United Pharmaceutical Co., Ltd
  • 7.2. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.3. Beijing Wansheng Pharmaceutical Co., Ltd
  • 7.4. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited
  • 7.5. Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd

8. Market Outlook of Lamivudine in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Lamivudine in China
  • Chart Approval Information of Lamivudine in China
  • Chart Sales Status of Lamivudine in China
  • Chart Sales Value of Lamivudine in China, 2010-2014
  • Chart Sales Value of Lamivudine in Some Regions in China, 2010-2014
  • Chart Sales Volume of Lamivudine in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Lamivudine for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by GlaxoSmithKline Pharmaceuticals (Suzhou) Limited in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by Burroughs Wellcome & Company (UK) in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Made by Fujian Cosunter in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Lamivudine Capsules in China, 2010-2014
  • Chart Sales Volume and Market Share of Lamivudine Tablets in China, 2010-2014
  • Chart Sales Volume and Market Share of Lamivudine Capsules in China, 2010-2014
  • Chart Price of Lamivudine Made by Beijing Wansheng Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Burroughs Wellcome & Company (UK) in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Anhui Biochem United Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Lamivudine Made by GlaxoSmithKline Pharmaceuticals (Suzhou) Limited in Some Chinese Cities in 2014
Back to Top